
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics Inc. exhibits a strong positive outlook due to the 8% quarter-over-quarter growth in prescriptions for Auvelity, bolstered by a direct-to-consumer campaign that is expected to sustain momentum through 2026. The company is preparing to scale its operations significantly, with an expanded sales force projected to enhance market penetration and drive towards a $1.6 billion sales opportunity in the upcoming years, particularly in the context of the anticipated launch of AXS-05 for Alzheimer's Disease. Additionally, Axsome's advancing pipeline and potential for achieving cash flow-positive status prior to mid-2026 further reinforce its growth prospects and overall market position within the central nervous system disorder therapeutics sector.
Bears say
Axsome Therapeutics Inc. faces substantial risks that contribute to a negative outlook on its stock, primarily tied to potential setbacks in its clinical trials and regulatory hurdles for its pipeline drugs, such as AXS-05 and AXS-12. The company may encounter challenges with market access for its product AUVELITY, and competition within a crowded market could hinder its commercial success, leading to lower-than-expected revenue projections. Additionally, there are concerns regarding the financial sustainability of ongoing operations given the significant expenditures on research and development alongside the risk of dilution and inability to secure timely approvals for its therapies.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares